Table 3 The somatic mtDNA mutations and clinicopathological characteristics of esophageal tumors.

M

42

24.75

T3N1M0

Alive, 51 month post surgery

III

0.67

0

F

57

8.6

T3N0M0

Alive, 48 month post surgery

IIA

1.56

1

T310C, 303→ 315 ins C

M

46

12

T2N1M0

10 month

IIB

0.71

0

M

65

0.2

T1N0M0

Alive, 48 month post surgery

I

2.7

0

M

50

19.5

T3N1M0

4 month

III

0.25

2

303–309 del C (C8→ C7/8), A1544T

M

70

0.65

T2N0M0

Alive, 4 month

IIA

1.6

0

M

52

36

T3N0M0

13 month

IIA

1.8

0

M

62

18

T4N0M0

12 month

III

1.6

0

M

66

12

T3N1M0

12 month

III

0.8

1

303–309 del C (C9/8→ C8/9)

M

73

9

T3N1M0

6 month

III

2.0

1

303–309 ins C (C8→ C8/9)

M

68

10

T2N1M0

34 month

IIB

1.8

0

M

51

2.55

T1N0M0

Alive, 60 month post surgery

I

3.1

1

G10500A

M

52

2

T1N0M0

3 month

I

1.5

0

M

60

11.25

T3N1M0

7 month

III

1.4

2

303–309 ins CC(C7→ C9/10), G9377A

M

67

26.4

T3N1M0

5 month

III

0.75

2

303–309 del C, A9182G

M

68

0.06

T2N0M0

Alive, 38 month post surgery

IIA

0.48

1

303–309 ins C (C7/8→ C7/8/9)

M

61

24.75

T2N1M0

20 month

IIB

3.1

1

303–309 ins C (C8→ C9)

M

38

20

T4N1M0

12 month

III

0.35

1

10941del TAACAACCCCC

M

68

36

T2N1M0

14 month

IIB

0.7

1

303–309 del CC (C9/10→ C7)

M

61

39

T3N1M0

8 month

III

0.7

0